{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"7.5","value":"6.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"}],"units":"Participants"}],"description":"Overall survival was measured for all participants from the time the participant received the first treatment of blinatumomab until death due to any cause or the date of the last follow-up. Participants who did not die were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. Overall survival was estimated using Kaplan-Meier methods. The median follow-up time with respect to overall survival was calculated by the reverse Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"MEDIAN","populationDescription":"Primary analysis set","reportingStatus":"POSTED","timeFrame":"Up to the data cut-off date of 10 October 2013; median observation time was 9.8 months.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}